drugset
drugset / Trial / NCT00189722

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

NCT00189722 ↗

Phase 2 Completed 160 enrolled Astellas Pharma Inc Astellas Pharma Europe B.V. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

Timeline

Start
—
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — Inhaled

Indications

asthma